Found 0 matching trials
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
PHASE2This is a prospective, single arm,single centre open-label, phase II study ...
Location
Nuclear Medicin Division, IRST IRCCS
Combination Targeted Radiotherapy in Neuroendocrine Tumors
NAThe primary aim of this project is to determine, what fraction of individua...
Location
University of Iowa
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
EARLY_PHASE1This is a prospective, pilot, single center, open-label study in patients w...
Location
University of California, San Francisco
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
PHASE1RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radio...
Location
Holden Comprehensive Cancer Center at University of Iowa
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
EARLY_PHASE1This is a safety study to determine the phase 1 starting dose of \[90\]Yttr...
Location
The Holden Comprehensive Cancer Center
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
PHASE2Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating...
Location
Chiara Maria Grana
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
PHASE1This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DO...
Location
University of Iowa Hospitals and Clinics
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
EARLY_PHASE1This study is designed to identify the best tolerated doses of \[131\]Iodin...
Status
Active Not Recruiting
Location
Holden Comprehensive Cancer Center